BridgeBio Pharma BBIO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's additional paid-in capital?
- BridgeBio Pharma (BBIO) reported additional paid-in capital of $2.11B in Q1 2026.
- How has BridgeBio Pharma's additional paid-in capital changed year-over-year?
- BridgeBio Pharma's additional paid-in capital increased by 9.0% year-over-year, from $1.94B to $2.11B.
- What is the long-term trend for BridgeBio Pharma's additional paid-in capital?
- Over 5 years (2020 to 2025), BridgeBio Pharma's additional paid-in capital has grown at a 15.0% compound annual growth rate (CAGR), from $1.02B to $2.06B.
- What does additional paid-in capital mean?
- The total amount of money investors paid for shares above their nominal par value.
- How do you interpret additional paid-in capital?
- Growth in this account reflects successful equity financing rounds or the exercise of employee stock options.
- How does additional paid-in capital compare across companies?
- High in biotech companies that have raised significant capital through multiple equity offerings.